Media, page-13

I agree no need for a phase 3 trial - what we know and has been said in the past that radiotherapy with chemo is the gold standard - OSL offers a lower toxicity to surrounding tissues, skin etc and more exact targeting of the pancreas for radiotherapy. So - why do you need a phase 3 trial when we already have shown that radiotherapy is the gold standard as part of the treatments - this is why Sirtex would not have needed a phase 3 trial also. I think the marketing spin is a great idea. It will drive end consumer demand for the product (the cancer patient) rather than physician demand - the NZ news item of the lady being still alive to celebrate Xmas with her family was heart warming. Cancer is a major target globally for ETF funds - immunotherapy, radiotherapy, imaging, CART - are all attractive investments. OSL if they can get some sales happening this will be a large return on the patient investor - I kind of liked what happened under the radar in 2020 - the foundations have been set to grow a sales base. Just how to execute the final steps now. I see a new website upgrade and is looking slick. Here is to upside in 2021. Lets hope ARKK will see its value and put it in its ETF portfolio and drive the stock to record highs.